{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:55:56Z","timestamp":1789750556954,"version":"4.0.1"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Pancreatic cancer was the third leading cause of cancer-related mortality in the United States in 2020 after lung and colorectal cancers. The prevalence of pancreatic cancer has been increasing and is projected to continue rising through 2040, with an estimated 355,317 additional cases expected. We present the case of an 81-year-old patient with metastatic pancreatic ductal adenocarcinoma (PDAC) who tolerated NALIRIFOX for a year with grade 1 adverse events. Case presentation: An 81-year-old Asian male presented with abdominal pain associated with weight loss and fatigue. An abdominal computed tomography (CT) scan showed a mass in the body of the pancreas measuring 3.5 cm with an infiltrative appearance invading the retroperitoneum and encasing the splenic artery. A biopsy confirmed poorly differentiated PDAC. The patient received 13 cycles of NALIRIFOX in a palliative setting over the course of one year, demonstrating excellent tolerance aside from minor toxicities, including worsening of pre-existing macrocytic anemia, treatment-related grade 1 neuropathy, diarrhea, and thrombocytopenia. A subsequent CT scan revealed disease progression, and the patient was switched to second-line therapy. However, per his preference, the patient was referred to hospice care and passed away a few days later. Conclusions: This case highlights the excellent tolerability of NALIRIFOX in an elderly patient, with minimal adverse events observed, which is uncommon among similar patient populations.<\/jats:p>","DOI":"10.3390\/reports8020069","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:59:16Z","timestamp":1747292356000},"page":"69","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An 81-Year-Old Geriatric Patient with Metastatic Pancreatic Cancer Demonstrating Excellent Response and Well Tolerance to NALIRIFOX: A Case Report and Literature Review"],"prefix":"10.3390","volume":"8","author":[{"given":"Bayan","family":"Khasawneh","sequence":"first","affiliation":[{"name":"Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-8351","authenticated-orcid":false,"given":"Abdullah","family":"Esmail","sequence":"additional","affiliation":[{"name":"Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtesam","family":"Al-Najjar","sequence":"additional","affiliation":[{"name":"Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seif","family":"El Beheary","sequence":"additional","affiliation":[{"name":"College of Natural Sciences, University of Houston, Houston, TX 77204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[{"name":"Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","unstructured":"(2024, June 12). Surveillance, Epidemiology and End Results Program, Available online: www.seer.cancer.gov."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bugazia, D., Al-Najjar, E., Esmail, A., Abdelrahim, S., Abboud, K., Abdelrahim, A., Umoru, G., Rayyan, H.A., Abudayyeh, A., and Al Moustafa, A.E. (2024). Pancreatic ductal adenocarcinoma: The latest on diagnosis, molecular profiling, and systemic treatments. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1386699"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.cgh.2020.02.054","article-title":"Burden of Pancreatic Cancer: From Epidemiology to Practice","volume":"19","author":"Khalaf","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1038\/emm.2016.6","article-title":"Pancreatic regulation of glucose homeostasis","volume":"48","author":"Wu","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular Pathogenesis of Pancreatic Cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.3390\/curroncol29110686","article-title":"Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening","volume":"29","author":"Badheeb","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Esmail, A., Badheeb, M., and Abdelrahim, M. (2023). Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. Pancreatic Cancer-Updates in Pathogenesis, Diagnosis and Therapies, IntechOpen.","DOI":"10.5772\/intechopen.110887"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Principe, D.R., Underwood, P.W., Korc, M., Trevino, J.G., Munshi, H.G., and Rana, A. (2021). The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.688377"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11864-021-00895-4","article-title":"Systemic Therapy for Metastatic Pancreatic Cancer","volume":"22","author":"Ettrich","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1615\/CritRevOncog.2020035971","article-title":"A Comprehensive Review of Diagnostic and Therapeutic Strategies for the Management of Pancreatic Cancer","volume":"25","author":"Sinha","year":"2020","journal-title":"Crit. Rev. Oncog."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic Pancreatic Cancer: ASCO Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fudalej, M., Kwa\u015bniewska, D., Nurzy\u0144ski, P., Badowska-Kozakiewicz, A., M\u0119kal, D., Czerw, A., Sygit, K., and Depta\u0142a, A. (2023). New Treatment Options in Metastatic Pancreatic Cancer. Cancers, 15.","DOI":"10.3390\/cancers15082327"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deng, D., Patel, R., Chiang, C.Y., and Hou, P. (2022). Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Cells, 11.","DOI":"10.3390\/cells11192952"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12705","DOI":"10.2147\/OTT.S220971","article-title":"Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress","volume":"13","author":"Barcellini","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"van Veldhuisen, E., van den Oord, C., Brada, L.J., Walma, M.S., Vogel, J.A., Wilmink, J.W., Del Chiaro, M., van Lienden, K.P., Meijerink, M.R., and van Tienhoven, G. (2019). Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 11.","DOI":"10.3390\/cancers11070976"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GIM.0b013e31818efd77","article-title":"Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review","volume":"11","author":"Palomaki","year":"2009","journal-title":"Genet. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: A practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"ref_27","first-page":"5501","article-title":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","volume":"47","author":"Tempero","year":"1987","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and Gemcitabine with Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kuroda, T., Kumagi, T., Yokota, T., Azemoto, N., Hasebe, A., Seike, H., Nishiyama, M., Inada, N., Shibata, N., and Miyata, H. (2017). Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: A multicenter review of 895 patients. BMC Gastroenterol., 17.","DOI":"10.1186\/s12876-017-0623-8"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/69\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:10Z","timestamp":1760031190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["reports8020069"],"URL":"https:\/\/doi.org\/10.3390\/reports8020069","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}